α干扰素与合成肽疟疾子孢子疫苗用于非免疫成人：40周后的抗体反应
Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.
作者信息
Stürchler D, Zimmer G, Berger R, Etlinger H, Fernex M, Matile H, Just M
机构信息
Clinical Research Department, F. Hoffmann-La Roche & Co. Ltd, Basle, Switzerland.
出版信息
Bull World Health Organ. 1990;68 Suppl(Suppl):38-41.
Adults with no known immunity to sporozoites received, i.m., at weeks 0 and 8 two single 200 micrograms doses of a peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3-TT) plus placebo (group 1) or interferon-alpha (IFN-alpha) (group 2) and were followed for antibody responses at weeks 4, 12 and 40. Peak antibody responses were observed at week 12. At week 40, a greater than or equal to 4-fold increase in antibody titre to sporozoites in IFA, or to (NANP)50 in ELISA was still detectable in 6 of 12 (50%) volunteers in group 1 and in 16 of 25 (64%) in group 2. Peak antibody titres in IFA and ELISA decreased with a rate of 0.8% and 0.5% per week, respectively.
对疟原虫子孢子无已知免疫力的成年人，于第0周和第8周通过肌肉注射接受两剂单剂量200微克与破伤风类毒素偶联的恶性疟原虫子孢子肽疫苗（(NANP)3-TT）加安慰剂（第1组）或干扰素-α（IFN-α）（第2组），并在第4、12和40周监测抗体反应。在第12周观察到抗体反应峰值。在第40周时，第1组12名志愿者中有6名（50%）、第2组25名志愿者中有16名（64%）仍可检测到间接荧光抗体试验（IFA）中针对子孢子的抗体滴度或酶联免疫吸附测定（ELISA）中针对(NANP)50的抗体滴度有大于或等于4倍的增加。IFA和ELISA中的抗体峰值滴度分别以每周0.8%和0.5%的速率下降。
Zotero 插件